Aegerion (AEGR) Q1 Juxtapid Sales 'Surprisingly Weak', Jefferies Says

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/1/2026

1. SPY
2. MDT
3. SPGI
4. USO
5. AAPL
6. ENOV
7. AON
8. NIO
9. AZN
10. EIX

Go back to Aegerion (AEGR) Q1 Juxtapid Sales 'Surprisingly Weak', Jefferies Says

Aegerion (AEGR) PT Lowered to $70 at Deutsche Bank Due to Slow Patient Growth

May 7, 2014 8:37 AM EDT

Deutsche Bank maintained a Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR) an reduced its price target to $70.00 (from $115.00). Analyst Robyn Karnauskas expressed caution due to slow patient growth.

"Juxtapid 1Q revenues at $27M were lower than consensus at $33.6M primarily due to lower sales in ex-US.... More

Cowen Downgrades Aegerion Pharmaceuticals (AEGR) to Market Perform

May 7, 2014 7:27 AM EDT

Cowen downgraded Aegerion Pharmaceuticals (NASDAQ: AEGR) from Outperform to Market Perform with a price target of $36.00 (from $85).

For an analyst ratings summary and ratings history on Aegerion Pharmaceuticals click here. For more ratings news on Aegerion Pharmaceuticals click here.

Shares of Aegerion Pharmaceuticals closed at $44.16 yesterday.

... More

Aegerion Pharmaceuticals, Inc. (AEGR) Tops Q1 EPS by 10c

May 6, 2014 4:34 PM EDT

Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) reported Q1 EPS of ($0.25), $0.10 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $27 million versus the consensus estimate of $33.58 million.

Highlights

Aegerion achieved $27.0 million in net product sales of JUXTAPID® (lomitapide) capsules in the first-quarter of 2014. 96% of net product sales in the first quarter were from the United States business, representing growth of 24% over net product sales from the U.S. business in the prior quarter. The Company now expects to achieve between $180 million and $200 million of net product sales... More